jandel t. allen davis - stiftung charité...foundation board of directors and served as the 2015...
TRANSCRIPT
![Page 1: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/1.jpg)
P: JANDEL T. ALLEN‐DAVIS
Vice President, Government,
External Relations and
Research, Kaiser
Permanente Colorado,
Denver
JANDEL T. ALLEN‐DAVIS
Jandel Allen‐Davis, MD, is vice president of Government,
External Relations and Research for Kaiser Permanente
Colorado. She leads the organization’s government
relations and regulatory affairs, community relations
and community benefit investment, clinical research
activities, stakeholder engagement, communications,
and advertising and marketing functions.
Dr. Allen‐Davis is board certified in obstetrics and
gynecology and after 25 years, transitioned from a
physician leader to Kaiser Permanente’s Health Plan
Leadership team. Her past roles at Kaiser Permanente
included associate medical director of external relations
for the Colorado Permanente Medical Group, regional
director of patient safety and physician chief of the
WheamaxRidge Medical Offices. Dr. Allen‐Davis was
elected to the Colorado Permanente Medical Group
Board of Directors in 1998 and chaired the board in her
final year.
A graduate of Dartmouth College and Dartmouth
Medical School, Dr. Allen‐Davis completed her residency
at Thomas Jefferson University Hospital in Philadelphia.
Before coming to work at Kaiser Permanente, she was
an assistant professor of obstetrics and gynecology at
the University of Colorado Health Sciences Center and
spent four years in the Indian Health Service in Tuba
City, Ariz., during which time she also served as member
and chair of the American College of Obstetrician
Gynecologists’ Committee on Alaska Native and Indian
Affairs.
Dr. Allen‐Davis believes health care will improve when
all the primary stakeholder groups — clinicians, patients,
elected officials, community leaders and employers —
can collaborate effectively to put the patient at the
center. “My vision is for Kaiser Permanente to be our
community’s most valuable partner in health. We want
to support dialogue and collaboration to help our
patients, our people and Colorado thrive,” she said.
Dr. Allen‐Davis is an active participant in the community,
including time spent on boards for the Denver Botanic
Gardens, Colorado Association of Commerce and
Industry Board of Directors, Denver Metro Chamber of
Commerce Board of Directors, Mile High United Way
![Page 2: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/2.jpg)
Board of Directors, Colorado Education Initiative Board
of Directors, The Denver Foundation Board of Trustees
and CU Foundation Board of Trustees. In 2013, she was
appointed to serve on the board of Grantmakers in
Health, a national organization focused on assisting
funders who are actively involved in supporting
nonprofits focused on community health. She is past
president of the Denver Metro Chamber Leadership
Foundation Board of Directors and served as the 2015
chair for the American Heart Association’s Go Red for
Women Campaign.
Dr. Allen‐Davis served on the Colorado State Board of
Medical Examiners from 2003–2011 and served as
president of the board from 2009‐2011.
Dr. Allen‐Davis is the proud recipient of the 2015
Colorado Black Women for Political Action, Excellence in
Community Service Award, the 25 Most Powerful
Women in Colorado from the Colorado Women’s
Chamber in 2013, the 2013 Colorado Black Women for
Political Action, Women Making History Award, the
2013 Metro Volunteers Community Impact Award, the
2012 Outstanding Women in Business in Health Care
from the Denver Business Journal, and is a member of
the 2012 Girl Scouts Women of Distinction inductees.
She was named 2000 Kaiser Permanente Physician
Volunteer of the Year and a “Top Doc” by 5280
Magazine for several years. In 2002, Dr. Allen‐Davis won
first place in the Professional Category of the “On My
Own Time” art show from the Colorado Business
Committee for the Arts.
In her spare time, Dr. Allen‐Davis is a fiber artist creating
original, hand‐painted quilts and fiber vessels. In
addition, she enjoys staying active, completing the
Kaiser Permanente Colfax half‐marathon in 2011.
![Page 3: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/3.jpg)
P: STEFAN BEHRENS
Co‐Founder & COO, Gyant,
San Francisco
STEFAN BEHRENS
Stefan is an repeat entrepreneur in the digital consumer
space. He started his career in strategy consulting and then
led two consumer companies to successful exits in mobile
gaming and e‐commerce. Stefan co‐founded GYANT, an
artificial intelligence service that improves access to health
information and care advice for millions of people. GYANT
works with payors and health systems to improve patient
navigation and engagement while improving effiency in
provider‐patient conversations.
![Page 4: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/4.jpg)
K: WOLFRAM BURGARD
Professor, Autonome
Intelligente Systeme,
Technische Fakultät, Albert‐
Ludwigs‐Universität
Freiburg, Freiburg
WOLFRAM BURGARD
Wolfram Burgard is Professor for Computer Science at
the University of Freiburg where he heads the
Laboratory for Autonomous intelligent Systems and the
Cluster of Excellence BrainLinks‐BrainTools. He
published two books and over 300 scientific publications
and is well‐known for his contribution to robotics and
artificial intelligence. He received the Leibniz Preis of the
Deutsche Forschungsgemeinschaft and an ERC Grant of
the European Research Council. He is Fellow of the AAAI,
the IEEE, and the EurAI and member of the Heidelberger
Akademie der Wissenschaften and Leopoldina Akademie
der Wissenschaften.
![Page 5: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/5.jpg)
K: ALBERTO CAMINERO
FERNANDEZ
McMaster University, Senior
Postdoctoral Fellow,
Hamilton, Canada
ALBERTO CAMINERO FERNANDEZ
Education:
2003‐2008: Bachelor‐ Biology. University of Leon (Spain)
2008‐2013: PhD – Microbiology and Molecular Biology.
University of Leon (Spain) 2014‐2018: Postdoctoral Fellow.
McMaster University (Canada)
Awards and Recognitions:
2013: Dr Schär Institute Award to the best original
publication about celiac disease. Sponsor: Dr Schar
Institute and Sociedad Española de Enfermedad Celiaca
2016: JA Campbell Research Young Investigator Award.
Sponsor: Canadian Celiac Association.
2017: Early career investigator Award. Sponsor: The
American Gastroenterology Association
Grants and Fellowships:
2008‐2010: PhD Research Fellowship. Sponsor: Sacyl‐Junta
de Castilla y León. Spanish Regional Program for Science.
2013: European Molecular Biology Organization (EMBO)
Short Fellowship. Sponsor: European Molecular Biology
Organization (EMBO). Award Amount: 30,000
2014‐2016. Sponsor: Canadian Institute of Health Research
(CIHR) and Canadian Association of Gastroenterology
(CAG). Award Amount: 90,000
2017: Farncombe‐Fellowship Salary Award. Sponsor:
Farncombe Family. Award Amount: 100,000.
2018: Biocodex Microbiota Foundation annual research
grant. Sponsor: Biocodex. Award Amount: 40,000
![Page 6: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/6.jpg)
C: CHARLES CAMERON
Senior Vice President,
Business Development,
Cooley, Boston
CHARLIE CAMERON
Charlie Cameron has over 25 years of business
development, investing and management consulting
experience in more than 30 countries. His experience
ranges from working on strategy with Fortune 500
companies, to counseling emerging technology and life
science companies, to venture investing. In addition, he
mentors emerging companies, judges numerous business
plan competitions and is a frequent speaker on innovation
and entrepreneurship. He founded the Hub Angel
Investment Group, which is on its fifth fund. He works with
a plethora of entrepreneurs, innovators and investors in
Europe, with special focus on DACH countries. Charlie is
also Senior VP of Strategy at Cooley LLP, a global law firm
with deep experience working with life science and tech
companies and venture funds. He is on the board of the
German American Business Council, Boston, the advisory
board of the German Accelerator Life Science, and several
other boards and advisory groups. During the past decade,
Charlie has built a global network of entrepreneurs,
investors, innovators, and others. He is a frequent speaker
on panels and at forums related to venture capital and
entrepreneurship. He has an MBA from MIT, an MPH from
Harvard University, and a BA, Economics‐honors, Phi Beta
Kappa, from the University of Massachusetts.
![Page 7: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/7.jpg)
K: ARIEL COHEN
Director of Business
Development & Alliances,
BiomX, Jerusalem Area
ARIEL COHEN
Dr. Ariel Cohen is Director of Business Development and
Alliances at BiomX, a microbiome drug discovery company.
Prior to his role in BiomX, Dr. Cohen co‐founded two
biotech companies: OnTimeBio (Diagnostics) and Ensof
Biosystems (Target discovery) and managed development
of three academic discoveries to drug development
companies. Dr. Cohen held business development roles at
Integra Holdings, Yissum (Hebrew University’s Tech
Transfer Office), and Aurum Ventures MKI. Prior to that Dr.
Cohen served as Senior Project Manager at Evogene
(NYSE:EVGN) an agriculture biotechnology company. Dr.
Cohen holds a Ph.D. in Systems Biology and an M.Sc. in
Computational Biology from the Weizmann Institute of
Science and has published in top peer‐reviewed journals,
including; Science, Nature and Cell.
![Page 8: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/8.jpg)
K: YOSSI COHEN
Microbiome Researcher,
DayTwo, Tel Aviv
YOSSI COHEN
PhD ‐ Dept. of Plant Pathology & Microbiology, Faculty of
Agriculture, Food & Environment, The Hebrew University,
Rehovot (In collaboration with UFZ‐ Helmholtz Centre for
Environmental Research Leipzig, Germany).
Thesis: "Deciphering predator‐prey interactions in complex
microbial communities"
Supervisor: Prof. Edouard Jurkevitch (Hebrew University of
Jerusalem)
M.Sc ‐ Dept. of Molecular Microbiology & Biotechnology,
Tel‐Aviv University (In collaboration with the Australian
Institute of Marine Science, Townsville).
Thesis: "Phage Therpay of Coral Disease in the Great
Barrier Reef,Australia"
Supervisors: Prof. Eugene Rosenberg (Tel‐Aviv Univeristy),
Dr. David Bourne (Australian Institute of Marine Science)
![Page 9: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/9.jpg)
K: ANNEGRET DE BAEY‐
DIEPOLDER
Venture Partner, Seventure
Partners, München
ANNEGRET DE BAEY‐DIEPOLDER
Annegret de Baey‐Diepolder is a Venture Partner at
Seventure Partners SA. Formerly she was co‐founder and
CEO of RNA‐based immunotherapeutics company Rigontec
GmbH, now Merck & Co., Inc..
As a life science industry consultant and former partner at
private equity and venture capital companies TVM Capital
and Gimv NV, she brings more than 15 years of experience
in the life science and venture capital sector.
![Page 10: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/10.jpg)
W: DOROTHÉE DÖPFER
Program Manager, Digital
Health Accelerator &
Community Building, Berlin
Health Innovation, BIH,
Berlin
DOROTHÉE DÖPFER
Dorothy has seven years of experience supporting
academic innovators and startups working in digital health,
medical devices, and therapeutics. She has worked with a
broad range of stakeholders such as scientists,
entrepreneurs, investors, and government representatives
from Germany, Europe, Israel, and the U.S. She has co‐
organized the Charité BIH Entrepreneurship Summit in
2017.
Before, she has been working in the field of science
management and Entrepreneurship at the Leibniz‐Institute
for Crystal Growth, a 3D printing startup as well as Stiftung
Charité and Freie Universität Berlin.
At the moment she is managing the Digital Health
Accelerator Program at Berlin Institute of Health and
supporting the Spark Berlin Program. Besides, she is
responsible for the community building in Berlin in the
field of Digital Health and is organizing a monthly event
with over a hundred participants: BIH Digital Health Forum.
Dorothy is an economic historian and sociologist by
training. Her thesis was focused on startups and their ways
of funding in the 19th century. Moreover, she holds a
Master of Public Health with core areas of cancer and
cardiovascular epidemiology & systematic reviews.
![Page 11: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/11.jpg)
C: DUSKA DRAGUN
Acting Director, BIH
Biomedical Innovation
Academy, Berlin
DUSKA DRAGUN
Duska Dragun is a full professor of medicine and
nephrology at the Medical Faculty of Charité
Universitätsmedizin Berlin and a senior attending of the
Department for Nephrology and Critical Care Medicine,
Charité Universitätsmedizin Berlin. Beside her clinical and
research appointment, she is founder and the director of
the Charité and Berlin Institute of Health Clinician Scientist
Program supporting 120 clinician scientist fellows among
all medical and surgical disciplines fostering translational
biomedical research with structured molecular medicine
curriculum and protected time for research.
Since 2016 she was appointed as acting director of BIH
Biomedical Innovation Academy. Her research is dedicated
to understand mechanisms of acute and chronic rejection
organ transplant patients and to identify mechanisms to
explain their therapy‐refractory course. With combined
approach of cohort studies in addition with complex
pathophenomics she is one of the pioneers of precision
medicine in organ transplantation.
She is recipient of numerous national and international
awards in nephrology, cardiovascular and transplantation
medicine for her research achievements as well as awards
for her society engagement exemplified by “Germany ‐
Land of Ideas” award for the BIH Charité Clinician Scientist
Program.
She has published more than 130 articles in leading peer‐
reviewed journals including those in Cell and New England
Journal of Medicine.
![Page 12: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/12.jpg)
P: JORGE JUAN FERNANDEZ
GARCIA
Director of Innovation, EIT
Health, Barcelona
Jorge Juan Fernandez Garcia
EXPERTISE: Healthcare & Life Sciences (Providers, Pharma,
Biotech, MedTech, Digital Health)
DISCIPLINES: Strategic planning and execution, Technology,
Innovation, Entrepreneurship, Biodesign, Lean Startup.
I have a dual affiliation:
[1] Director E‐Health and Health 2.0, Hospital Sant Joan de
Déu ‐ Barcelona Children's Hospital
(www.sjdhospitalbarcelona.org)
[2] Head of Academics, Moebio (www.moebio.org)
SPEAKER
Conferences:
Doctors 2.0 & You (Paris); Health 2.0 (London, Barcelona);
Dubai Digital Health Live (Dubai, EAU)
Charité Entrepreneurship Summit (Berlin); eyeforpharma
(Philadelphia); Rethinking Healthcare (Berlin)
Companies:
Lectured at top 500 companies: pharma (Pfizer, Roche,
Sanofi, LEO Pharma), medtech (Medtronic), etc.
Topics:
+ Business Model Innovation in Life Sciences and Health
Care
+ Trends for the Future of Medicine
+ Digital Healthcare
MENTOR
Healthcare and Life Sciences: MIRU Medical, Devicare,
usMIMA, ilS (Insights in Life Sciences), Kocoon, my qup,
Meelk, Tractivus, Mimetis (previously Subtilis
Biomaterials),
Tech industry: Adman Media, Inqbarna, ClickEdu
Consumer goods: Pegaso
ADVISOR / BOARD MEMBER
Exovite (Digital Manufacturing for rehabilitation)
ACCELERATORS & CORPORATE VENTURING
Healthbox
HealthXL
MIT‐Barcelona Mentoring Program
Singularity University ‐ Call to Innovation ‐ Spain
![Page 13: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/13.jpg)
ASSOCIATIONS
BME‐IDEA Europe
iSPI (International Society for Pediatric Innovation)
GENiE (Global Educators Network for Health Care
Innovation and Entrepreneurship) Group
![Page 14: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/14.jpg)
P: ROBERT FRIGG
Visiting Professor, Berlin
Institute of Health, Berlin
ROBERT FRIGG
Prof. Dr. h.c. mult. Robert Frigg has vast experience in
product development in the medical device industry. From
2004 – 2012, he was the former CTO of Synthes with global
responsibility for technology and innovation. Prior to that
he held leadership product development positions at
Mathys and the AO/ASIF Foundation in Davos, as well as
the position of Director at the AO/ASIF Development
Institute in Davos. Dr. Frigg has received numerous awards
in recognition of his contributions to the medical device
industry.
![Page 15: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/15.jpg)
W: SARAH‐MADELEINE
GABLER
UnternehmerTUM,
Innovation Consultant,
Munich
SARAH‐MADELEINE GABLER
UnternehmerTUM, Innovation Consultant, Munich
![Page 16: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/16.jpg)
P: Head, Innovation Center,
Merck Group, Frankfurt am
Main
MICHAEL GAMBER
Michael Gamber is the Head of the Merck Innovation
Center and worked on the development of the concept of
the Innovation Center for more than three years in his role
as Merck Inhouse Consultant before taking over the lead of
the Innovation Center in 2015.
With an academic background in business administration,
information management and business education he
joined the Inhouse Consulting department of Merck in
2010. In this role Michael worked on different projects
dealing with innovation management, strategy and
business process management. Prior to that Michael held
different international consulting roles at PA Consulting
Group, Capco and PricewaterhouseCoopers. Michael
received his diploma from the University of Mannheim in
2005.
![Page 17: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/17.jpg)
W: CRAIG GARNER
CRAIG GARNER
Prof. Craig Garner received his doctoral degree in
Biochemistry at Purdue University and did his postdoctoral
studies at the Friedrich Miescher Institute in Basel, CH and
was a junior group leader at the Center for Molecular
Neurobiology in Hamburg. His most recent faculty
appointment was at Stanford University as Professor in the
Department of Psychiatry and Behavioral Science, where
he co‐directed the Stanford Down syndrome Center. In
2014, he became a Scientist/co‐Speaker of the DZNE‐
Berlin: German Center for Neurodegenerative diseases and
Professor at the Charité –Universitätsmedizin Berlin. In
2015, he co‐founded SPARK‐Berlin to help educate
academic scholars about translation and
entrepreneurship. He has also founded three biotech
companies, “Balance Therapeutics”, “Stealth Biosciences”
and Navan Technologies. He maintains an active basic
research program focused on the molecular and
physiological mechanisms of synapse assembly and
function in health and neurodegenerative diseases.
![Page 18: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/18.jpg)
K: JOHN E. GREENWOOD AM
Medical Director, Adult Burn
Service, Royal Adelaide
Hospital, Adelaide
JOHN E. GREENWOOD AM
John Greenwood AM is an English‐trained plastic surgeon
who graduated from the University of Manchester in 1989
and now working full‐time in burn care as the Medical
Director of the Adult Burn Centre of the Royal Adelaide
Hospital in Adelaide, South Australia. He has been
developing skin replacement products, utilising the
NovoSorb biodegradable polyurethane platform, since
2004. He was appointed Member of the Order of Australia
(AM) following his work leading Australia’s only Burns
Assessment Team after the carnage of the 2002 Bali
Bombings which killed 202 civilians. He was the 2016 South
Australian Australian of the Year.
![Page 19: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/19.jpg)
K: JASMIN GÜNGÖR
Partner, DLT Capital, Munich
JASMIN GÜNGÖR
Jasmin Güngör is partner at DLT Capital, a consulting
company that specializes on ICO and blockchain advisory
services, investor relations and research. She first got to
know Bitcoin in 2011 and has been watching the crypto
market ever since, following all technical innovations with
much interest. Next to her adivsory position at DLT Capital,
she also speaks at conferences and meetups. Jasmin
studied International Business Sciences at the University of
Innsbruck and the Bogazici University in Istanbul. Between
2014 and 2018 she has been impact investing manager at
Don Bosco. Other stations in her life have been: the
Business Agency of Lower Austria, the University of Vienna
as well as lecturing activities on behalf of the Vienna Stock
Exchange.
![Page 20: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/20.jpg)
K: ROBERT GÜTIG
Professor, Charité ‐
Universitätsmedizin Berlin &
Berlin Institute of Health,
Berlin
ROBERT GÜTIG
Postgraduate positions
Apr. 2018 – present: Full Professor (W3), Charit´e Medical
School Berlin & Berlin Institute of Health.
Nov. 2011 – Mar. 2018: Max Planck research group leader
(topic free), Max Planck Institute of Experimental
Medicine.
Apr. 2005 – Jul. 2011: Postdoctoral & Associate researcher,
Hebrew University of Jerusalem, Racah Institute of Physics
and Interdisciplinary Center for Neural Computation.
Nov. 2006 – Feb. 2007: Visiting researcher, Harvard
University, Center for Brain Science.
Mar. 2004 – Mar. 2005: DFG project leader, Humboldt
University Berlin, Institute for Theoretical Biology.
Mar. 2004 – Jul. 2004: Visiting researcher, Hebrew
University of Jerusalem, Interdisciplinary Center for Neural
Computation.
Jul. 2003 – Feb. 2004: Postdoctoral researcher, Humboldt
University Berlin, Institute for Theoretical Biology.
Academic education & Degrees
Dec. 2002: “Doctor rer. nat.” (PhD) (University of Freiburg,
Germany).
Oct. 1999 – Dec. 2002: University of Freiburg – PhD
program in Neuroscience.
Oct. 1999: “Vordiplom” (BSc) in Psychology (University of
Heidelberg, Germany).
Oct. 1997 – Sep. 1999: University of Heidelberg –
Psychology, Statistics.
Dec. 1997: Master of Philosophy (University of Cambridge,
UK).
Oct. 1996: – Sep. 1997 University of Cambridge – Masters
program in Theoretical Physics.
Oct. 1995: “Vordiplom” (BSc) in Physics (Free University
Berlin, Germany).
Oct. 1993: – Sep. 1996 Free University Berlin – Physics,
Computer Science, Mathematics.
May, 1993: “Abitur” (A‐Levels) (Berlin, Germany).
May, 1991: High School Diploma of Graduation (Phoenix,
Arizona, USA).
PhD Thesis: Cooperative Dynamics in Neural Networks –
Models and Analyses Based on Interacting Point Processes.
Advisor: Prof. Dr. Aertsen, Institute of Biology III, University
of Freiburg.
Masters Thesis: On Scalar Quantum Fields Interacting with
![Page 21: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/21.jpg)
a Moving Dielectric. Advisor: Prof. Dr. Eberlein, Cavendish
Laboratory, University of Cambridge.
Peer reviewed funding & Awards (selected)
Feb. 2017 2016: AAAS Newcomb‐Cleveland Prize for best
Science publication of the year.
Nov. 2011 – Nov. 2018: Independent Max Planck Research
Group (“Free Floater”).
Sep. 2014: German Science Foundation Grant (DFG, GU
605/3‐1 “Scientific Symposium”).
Sep. 2010 – Nov. 2010: KITP & Rice Family Fund Award
(Emerging Techniques in Neuroscience Program).
Jul. 2008 – Jul. 2011: German Science Foundation Grant
(DFG, GU 605/2‐1 “Forschungsstipendium”).
Nov. 2005 – Nov. 2007: Hans Jensen Named Fellowship,
Minerva Foundation (Max Planck Society).
Mar. 2004 – Mar. 2005: German Science Foundation Grant
(DFG, GU 605/1‐1 “Eigene Stelle”).
Dec. 1993 – Feb. 2003: Undergraduate & PhD scholarships
(German Academic Scholarship Foundation)
![Page 22: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/22.jpg)
MODERATOR
JOHN HALLINAN
Chief Business Officer,
Massachusetts
Biotechnology Council,
Cambridge, MA
JOHN HALLINAN
John Hallinan joined MassBio in 2012 as the Chief Business
Officer and oversees the MassBio Innovation Services
programs.
John’s fiscal experience in the life sciences and software
industries reflect positions of increasing responsibility
across a broad range of strategic and operational
disciplines. His background encompasses venture
financings, corporate development, technology licensing,
and mergers and acquisitions.
Prior to MassBio, John was the Chief Financial Officer at
Cytel, a leader in the design and implementation of
adaptive clinical trials, and he had been active with
MassBio—serving on the Economic Development Advisory
Group and as co‐chair of the Finance Committee &
Entrepreneur’s University.
Before joining Cytel, John served as CFO at Signet
Laboratories, a leading supplier of diagnostic assays to the
pharmaceutical and biotech industries. Prior to Signet,
John was interim CFO at Cambium Learning, a private
equity‐backed publishing company that completed two
acquisitions during his tenure. John was the Chief Financial
Officer of AnVil, Inc. a venture‐funded silico drug discovery
company, where he led the company’s healthcare market
business development efforts. At CambridgeSoft
Corporation, John rose to CFO of that leading pharma/bio
applications and enterprise solutions supplier. As
Animation Technologies’ CFO, he guided the company’s
first and second rounds of venture funding.
John currently sits on the Advisory Board of MTTC (the MA
Technology Transfer Center).
John holds a BBA from St. Bonaventure University and is a
certified public accountant. He lives with his wife Denise in
Marlborough, MA.
![Page 23: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/23.jpg)
K: DIETMAR W. HUTMACHER
QUT Chair in Regenerative
Medicine, Institute of Health
and Biomedical Innovation,
Queensland University of
Technology, Brisbane
DIETMAR W. HUTMACHER
Dietmar W Hutmacher is Distinguished Professor and Chair
of Regenerative Medicine at the Institute of Health and
Biomedical Innovation at the Queensland University of
Technology. He directs the ARC ITTC in Additive
Biomanufacturing and QUT Centre in Regenerative
Medicine. D/Prof Hutmacher has eminent track record in
biomedical engineering, tissue engineering & regenerative
medicine. D/Prof Hutmacher did build a research program
that gained global recognition and his interdisciplinary
network goes beyond current mainstream collaboration
configurations. D/Prof Hutmacher’s international standing
and impact on the field are illustrated by his publication
record (more than 300 journal articles, 14 edited books,
>50 book chapters and citation record in scopus >26.000
citations, h‐index 80. He is one of very few academics in
the field of regenerative medicine who has taken a
research program from bench to bedside and
commercialization.
![Page 24: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/24.jpg)
C: ANULA JAYASURIYA
Founder, eXXclaim Capital &
EILSF, Los Altos, CA
ANULA JAYASURIYA
Anula Jayasuriya is an experienced health care and Life
Sciences executive and investor. Anula’s expertise consists
of a unique combination of business, basic science and
medical knowledge.
Recognizing the growing yet under‐invested opportunity in
Women’s Health, in 2013 Anula launched eXXclaim Capital,
focused on catalyzing innovation, entrepreneurship and
investment in this field and has already made several
investments. In 2006 Anula co‐founded the “Evolvence
India Life Science Fund” (EILSF), to make investments in
pharmaceutical, biotechnology, medical device and
contract services companies based in India. EILSF has
garnered three successful exits to date and India Life
Science 11 has had its first close.
She was previously a partner with Skyline Ventures in Palo
Alto, and prior to that with the German – US venture
capital firm TVM, in San Francisco. Her prior positions
include VP‐Corporate development at Genomics
Collaborative Inc., and Vice President, Global Drug
Development at Hoffman‐La Roche for opportunistic
infections in AIDS and Transplantation. Anula received a BA
from Harvard summa cum laude, and an MD and PhD (in
Microbiology and Molecular Genetics) from Harvard
Medical School. She interned in Pediatrics at Boston
Children’s Hospital and received an MBA with distinction
from Harvard Business School. Anula also has a M. Phil. in
pharmacology from the University of Cambridge, in
England. Anula sits on the boards of Ocimum BioSolutions,
and MapMyGenome, Hyderabad and nVision, San
Francisco. She was previously a board member of Health
Care Global which was exited to Temasek, Lipomics which
was acquired by Tethys and Triesta BioSciences which was
acquired by Health Care Global. She also serves on several
non‐profit boards, including Astia, EPPIC, and The Gruter
Institute for Law and Behavioral Research.
![Page 25: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/25.jpg)
W: LAURA JOHNSON
Head of Industry
Cooperations &
Partnerships, Berlin Health
Innovation, BIH, Berlin
LAURA JOHNSON
Dr. Laura Johnson PhD is the head of Industry Cooperations
and Partnerships at the Berlin Institute of Health. Educated
in the UK in Medicine and going to complete a Masters
then PhD in Augmented Reality in Neurosurgery she left
the UK to start a career with Siemens Healthcare in the
USA. Focusing for the next 10 years on clinical
collaborations and project management for Siemens she
worked in the USA, Canada, China, Hong Kong Taiwan and
Korea building up and heading a regional team in Asia to
handle the growing market of industry‐academic
partnerships and clinical research, now more commonly
known as Medical Science Liaison. Back in Europe Laura
worked for French medical device startup for 3 years, for
Startup Bootcamp Digital Health Berlin in 2017 and in 2018
joined the Berlin Institute of Health to help develop and
strengthen strategic partnerships at Charité, MDC and the
BIH.
![Page 26: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/26.jpg)
P: ARTHUR KAINDL
General Manager, Digital
Health Services, Siemens
Healthineers, Siemens
Healthcare, Erlangen
ARTHUR KAINDL
Dr. Arthur Kaindl has been General Manager of Digital
Health Services at Siemens Healthineers since December
2015. Dr. Kaindl previously worked as Chief Executive
Officer for the Imaging Informatics Business at Siemens AG
Healthcare Sector. He joined Siemens AG in 1995 after
finishing his studies at the Friedrich‐Alexander University in
Erlangen‐Nuremberg and a master’s degree in Ceramics
Engineering from the New York State College at Alfred
University. Since finishing his Ph.D. in Electrical Engineering
in 2001 from Hannover University, Dr. Kaindl has held
various management positions in the field of Magnetic
Resonance.
![Page 27: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/27.jpg)
P: ANNA KLAPWIJK
Consultant, Dutch
Blockchain Team, Deloitte,
Den Haag
ANNA KLAPWIJK
Anna Klapwijk is consultant in the Dutch Blockchain team
of Deloitte. She has been educated as a Strategic Product
Designer at the Technical University of Delft, where she
specialized in Medesign as well as Entrepreneurship. After
graduating on blockchain in healthcare at Deloitte, she
started working there as a strategist in the blockchain
team. She prefers to term ‘creative strategist’ and
combines knowledge of technology, business and people
to develop services and solutions and in the blockchain
space. The focus areas she works on are healthcare, life
sciences and supply chain. Anna is an adventurer, explorer
and a bit of a rebel.
![Page 28: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/28.jpg)
W: LENA KRZYZAK
Investment Manager, High‐
Tech Gründerfonds, Bonn
LENA KRZYZAK
Lena joined HTGF in 2016 as an Investment Manager in the
Life Science Team, and is currently responsible for sourcing
and the completion of new early‐stage investments. In
addition, she has four portfolio companies, active in the
fields of medical technology, drug development,
biotechnology and digital health. Before coming to HTGF,
she worked as Postdoctoral Researcher at the University
Hospital in Erlangen, and obtained her PhD in Immunology
within a DFG‐funded Fast‐track PhD program at the
Friedrich‐Alexander University Erlangen‐Nürnberg. The
thesis resulted in several publications in renowned journals
including The Journal for Experimental Medicine. Lena
completed her Bachelor’s degree from the Georg‐August
University Göttingen, and also spent time studying abroad
in Umeå (Sweden) and Singapore.
![Page 29: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/29.jpg)
K: MAX LU
President & Vice‐Chancellor,
University of Surrey, Surrey
MAX LU
Professor Max Lu has been President and Vice‐Chancellor
of University of Surrey since April 2016. Previously he was
Provost and Senior Vice‐President at the University of
Queensland, Australia. He has been appointed to the Prime
Minister’s Council for Science and Technology, the Boards
of UK Research and Innovation, National Physical
Laboratory, Universities UK, and serves on the Leadership
Council of the National Centre for Universities and
Business. He is Deputy Lieutenant of County of Surrey.
Professor Lu lectured at Nanyang Technological University
from 1991 to 1994, and had held academic and leadership
positions at the University of Queensland from 1994 to
2016, rising from senior lecturer to chair professor. He
founded the Australian Research Council Centre of
Excellence for Functional Nanomaterials and served as its
inaugural director for 8 years. He was awarded the
Australian Research Council (ARC) Federation Fellowship
twice, respectively, in 2003 and 2008.
As a double Highly Cited Researcher in both Materials
Science and Chemistry, he has published over 500 journal
papers on nanomaterials (h=111 and over 50,000 citations
@Scopus). He is co‐inventor of more than 20 granted
international patents. He has been honoured with
numerous awards including Orica Award, RK Murphy
Medal, Le Fevre Prize, ExxonMobil Award, China
International Science and Technology Award, Japan
Chemical Society Lecture Award, Chemeca Medal, and P.V.
Danckwerts Lecture. He was also recently honoured with a
Medal of the Order of Australia (Officer in the General
Division) for his distinguished service to education and
international research in the field of materials chemistry
and nanotechnology, to engineering, and to Australia‐
China relations.
Professor Lu has served on many government committees
and advisory boards including those under the Australian
Prime Minister’s Science, Engineering and Innovation
Council, ARC College of Experts, Australian Synchrotron,
Stem Cells Australia. He is Fellow of Institution of Chemical
Engineers, Royal Society of Chemistry, Australian Academy
of Science, Australian Academy of Technological Sciences
and Engineering, and World Academy of Science.
![Page 30: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/30.jpg)
P: MICHAEL MCGRAIL
Partner, Cooley, Frankfur
MICHAEL MCGRAIL
Michael J. McGrail's practice includes the representation of
company and investor clients in a full range of corporate
legal projects, including mergers and acquisitions, private
financings, corporate partnerships and technology
licensing. He counsels companies and investors in many
industries, with a particular focus on medical devices and
life sciences. Mike is fluent in German, and a significant
portion of his practice is devoted to international
transactions.
Education
Boston College Law School, JD, 2001, cum laude
Northeastern University, BA, 1993, magna cum laude
Bar Admissions
District of Columbia
Massachusetts
Memberships
German American Business Counse
![Page 31: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/31.jpg)
W: MARINA LEONIE
MOSKVINA
Expert Personal
Development & Coaching,
Entrepreneurship & Tech
Education,
UnternehmerTUM, Munich
MARINA LEONIE MOSKVINA
Marina Leonie Moskvina works in the field of leadership
and business coachings, personel development as well as
Human Resources Consulting for over five years. She is also
responsible for formats in the field of MedTech and
Healthcare Innovation in corporation with hospitals in
Munich. She also stays in close touch with the
entrepreneurial scene and supports startups and
accelerator programs as a HR mentor and consultant.
![Page 32: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/32.jpg)
P: DOMINIK N. MÜLLER
Head of Research Group,
Experimental and Clinical
Research Center, Max
Delbrück Center for
Molecular Medicine, Berlin
DOMINIK N. MÜLLER
Education / Training
1991: Free University of Berlin, Pharmacy
1996: Free University of Berlin, PhD, Pharmacy
2004: Charité, Berlin, Postdoctural thesis, Experimental
medicine
Positions and Honors (chronological order)
1996 – 2000 Post‐doc Research Assistant, Volhard Clinic,
Berlin, Germany
2001 – 2004 Post‐doc Research Assistant, Max‐Delbrück‐
Center, Germany
2004 – 2010 Group Leader, Delbrück Fellow at Max‐
Delbrück‐Center
2010 ‐ 2012 Professor, Experimental Medicine, Friedrich‐
Alexander University, Nikolaus‐Fiebiger Center, Erlangen,
Germany
2010 ‐ Group Leader, Experimental and Clinical Research
Center at Max‐Delbrück‐Center
Honors and Activities
2000 Young investigator award of the German
Hypertension Society
2001 Poster Prize of the German Nephrology Society
2002 New Investigator Award for European Fellows,
Council for High Blood Pressure Research, American Heart
Association
2002 Dieter‐Klaus Förderpreis of the German
Hypertension Society
2004 Editorial Board “Hypertension”
2006 ADUMED Forschungspreis
2007 Renin Academy Young Investigator Award
2009 Best basic science paper of 2008 – Hypertension
2013 APL professorship at Charité
2013 Co‐Founder of Omeicos Therapeutics
2013 AHA HBPR committee Liaison, Coordinator,
International Mentoring
2013 AHA HBPR Fall Conference Program on the
Leadership Committee
2018 Associate Editor “Cardiovascular Research”
Research Interest
![Page 33: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/33.jpg)
Dominik N. Müller (PhD) heads a translational group at the
Experimental and Clinical Research Center & Max‐Delbruck
Ctr for Molecular Medicine in the Helmholtz Association.
The group’s major research interests are the renin‐
angiotensin system, the immune system and how both
systems cause hypertension‐induced target‐organ damage.
Recent work has extended the concept analyzing how
environmental factors such as a high salt affect the
microbiome, immune cells, target organs, and
autoimmunity.
![Page 34: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/34.jpg)
C: MARKUS MÜSCHENICH
Co‐Founder & Managing
Partner, Flying Health
Incubator, Berlin
MARKUS MÜSCHENICH
Dr. Markus Müschenich is a board certified pediatrician
and holds a Master degree in Public Health. For more than
10 years he has been a board member of non‐profit and
private hospital groups He is founding and board member
of the German Association for Internet Medicine and
Venture Partner in the investment team of Peppermint
Venture Partners.
Dr. Markus Müschenich is Managing Partner of the Flying
Health Incubator which focuses on digital health startups
developing Digital Biomarkers & Software‐as‐a‐Drug
solutions. Dr. Markus Müschenich is regarded as a
specialist for digital medicine of the future.
![Page 35: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/35.jpg)
P: DANIEL NATHRATH
Founder & CEO, Ada Health,
Berlin
DANIEL NATHRATH
Daniel Nathrath is Co‐Founder & Chief Executive Officer of
Ada, an AI powered health guide that helps people
understand their health and navigate to the next
appropriate steps in their care.
As a serial entrepreneur in consumer technology, Daniel
helped drive the shift of Ada from a purely doctor‐facing
tool to a global consumer app after seeing a huge need in
the market. Ada has become one of the world’s fastest
growing medical apps, supporting millions of individuals
globally. Ada’s platform also supports clinicians, research
institutions and health systems to improve patient
outcomes and inform clinical decision making.
Daniel has lived and worked in Germany, Denmark, the UK
and the USA as Founder, Managing Director and General
Counsel at several internet startups. He also spent some
years as a Consultant at the Boston Consulting Group. He
trained as a lawyer in Germany and the USA, where he was
a Fulbright Scholar, and earned his MBA from the
University of Chicago.
![Page 36: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/36.jpg)
P: KEVIN OUTTERSON
Professor, Boston University
& Executive Director &
Principal Investigator, CARB‐
X Boston
KEVIN OUTTERSON
Professor Outterson teaches health care law at Boston
University, where he co‐directs the Health Law
Program. He serves as the Executive Director and Principal
Investigator for CARB‐X, a $455M international public‐
private partnership to accelerate global antibacterial
innovation. Key partners in CARB‐X include the US
Government (BARDA & NIAID) and the Wellcome Trust.
His research work focuses on the law and economics of
antimicrobial resistance. He is an Associate Fellow at the
Royal Institute of International Affairs (Chatham
House). Professor Outterson was a founding member of
the Antimicrobial Resistance Working Group at the
CDC. He was a senior consultant on the Eastern Research
Group study on antibiotic markets for FDA/HHS. Starting in
October 2014, he joined DRIVE‐AB, a three‐year €9 million
project on antibiotic business models sponsored by the
European Union’s Innovative Medicines
Initiative. Professor Outterson also serves on the Advisory
Panel for the Longitude Prize for an inexpensive rapid
point‐of‐care antibiotic diagnostic. Professor Outterson
was given the 2015 Leadership Award by the Alliance for
the Prudent Use of Antibiotics for his research and
advocacy work. He has testified before Congress,
Parliamentary working groups, WHO, and several state
legislatures.
He serves as the faculty co‐advisor to the American Journal
of Law & Medicine; past chair of the Section on Law,
Medicine & Health Care of the American Association of
Law Schools; former Editor‐in‐Chief of the Journal of Law,
Medicine & Ethics; and the current President of the Board
of the American Society of Law, Medicine &
Ethics. Professor Outterson is an occasional author for the
New England Journal of Medicine on health law topics and
has published extensively in medical, legal and health
policy journals. He practiced law for a dozen years, at
McDermott, Will & Emery (Chicago) and Baker Donelson
(Nashville).
![Page 37: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/37.jpg)
W: PATRIZIA PAWELEK
Project Leader,
pre‐INCUBATION
Entrepreneurial Network,
UnternehmerTUM, Munich
PATRIZIA PAWELEK
Patrizia Pawelek is responsible for early stage start up
ideas and teaming as a coach and trainer. She is focused on
challenging Med Tech Innovations in all aspects of
Entrepreneurship ‐ to make them start up ready.
![Page 38: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/38.jpg)
P: JAMES PEYER
Managing Partner, Apollo
Ventures, Hamburg
JAMES PEYER
James Peyer, PhD is the Founder of Apollo Ventures, an
impact‐driven investment firm focused exclusively on
creating medicines that can extend human lifespan and
healthspan by treating the causes of the aging process.
Apollo founds companies with scientists, invests in early
stage therapeutics projects, and contributes time and
expertise to all aspects of early stage biotech companies.
Apollo has quickly become the largest investor focused on
aging biology in the world.
Before Apollo, James worked with McKinsey & Company in
New York, where he focused on building new biotech
companies and developing cell therapies. James earned his
doctorate in stem cell biology at University of Texas
Southwestern in Dallas, where he was a National Science
Foundation GRFP Fellow; he received his undergraduate
degree in Immunology with Special Honors from the
University of Chicago.
![Page 39: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/39.jpg)
C: ANNIKA PIERSON
Co‐Founder & Chief
Operating Officer, Advise
Connect Inspire, Cambridge,
MA
ANNIKA PIERSON
Through various roles in the German and the US healthcare
industries, Annika has extensive experience building strong
global networks by bringing together investors,
entrepreneurs, and senior industry executives. As Chief
Operating Officer of ACI, she facilitates the successful US
market entry of emerging companies from Europe and
connects US‐based startups with European investors and
industry groups. Prior to joining the German Accelerator
Life Sciences (GALS) and founding ACI in Cambridge, MA,
Annika headed the innovation and entrepreneurship
programs of Charité Foundation in Berlin, including the
highly successful international healthcare industry
conference, Charité Entrepreneurship Summit.
![Page 40: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/40.jpg)
P: HANS RAFFAUF
COO, BioWink, Berlin
Hans Raffauf
Hans Raffauf is a co‐founder of Clue , a company that he
started with his wife Ida Tin . Clue develops an app
allowing women to accurately keep track of their fertility
cycles. In addition Hans co‐founded hy! , a creative event
series, to support and connect Europe's startup scene.
Prior to that Hans helped set up the Berlin Hardware
Accelerator and has been helping corporates like Deutsche
Telekom and Axel Springer with their outreach to
innovative startups. Hans founded betapitch , Berlin's
legendary startup competition as well as Berlin Tech
Meetup. He worked with solar startup Changers and was
also one of the founders of Palomar5, a Deutsche Telekom
backed open innovation project to explore future work
environments.
Hans has been featured with his projects in The New York
Times, DailyMail, Wall Street Journal, San Francisco
Chronicle, WIRED, TechCrunch, GigaOM, BILD, Spiegel
Online and Manager Magazin
![Page 41: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/41.jpg)
C: JOACHIM RAUTTER
Co‐Founder, Peppermint
VenturePartners, Berlin
JOACHIM RAUTTER
Joachim Rautter is a co‐founder of Peppermint
VenturePartners and Managing Partner of Peppermint
Charité Biomedical Fund.
Prior to the launch of Peppermint VenturePartners, he was
Investment Director at Peppermint Holding GmbH. There
he was responsible for the investment activities of the
Peppermint Venture Capital Fund. He has over 15 years of
experience in the venture capital industry and was
Chairman of the Supervisory Board of Scienion AG, as well
as Chairman of the Advisory Board of JADO Technologies
GmbH and Innolume GmbH. He is currently Chairman of
the Board of CEVEC Pharmaceuticals GmbH and CellAct
Pharma GmbH, and also serves on the Board of
CryoTherapeutics GmbH and Labfolder GmbH.
Prior to joining Peppermint, he guided innovative start‐ups
in the field of start‐up financing and entrepreneurial
development. In addition, he was involved in key functions
in the design and implementation of regional innovation
strategies.
Joachim Rautter has a degree in physics and completed his
PhD at the Max Volmer Institute for Biophysical Chemistry
at the Technical University of Berlin.
![Page 42: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/42.jpg)
W: WALTER L. RUST
Lawyer and Notary, MOCK
Rechtsanwälte, Berlin &
Attorney at Law, New York
WALTER L. RUST
Main Practice: Corporate Law, special focus life science
companies. For more than 30 years advice on formations
of companies, venture financing up to IPO and trade sale.
Advice on the drafting of articles of associations,
shareholders’ agreements, participation agreements as
well as license and distributor agreements
Sale of German companies to US investors.
Lecturer Berlin School of Economics and Law and Technical
University, Berlin
Chairman of various Supervisory Boards
Partner of a mid‐size partnership of lawyers and notaries in
Berlin. Numerous clients in technology sector
![Page 43: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/43.jpg)
W: JOHANNES SCHNEIDER LITTFELD
Peppermint
VenturePartners, Board
Member, Berlin
JOHANNES SCHNEIDER LITTFELD
Johannes Schneider Littfeld, MSc has been in
endocrinology research at the Universities Giessen and
Minneapolis, before he started his industry career at the
management consulting firm Sudler&Hennessey. He than
has been Managing Director and CEO with Ferring
Biotechnik, Disetronic Medical Systems and Becton
Dickinson. He served as Corporate Vice President at Otto
Bock HealthCare and is Board Member of several
international Healthcare companies.
![Page 44: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/44.jpg)
P: MICHAEL SCHÜTZ
Executive Director, Center
for Musculoskeletal Surgery,
Charité ‐ Universitätsmedizin
Berlin, Berlin
MICHAEL SCHÜTZ
Professor Michael Schuetz is a practicing orthopaedic
surgeon and research leader in the field of trauma care and
orthopaedic trauma research. Since April 2016 he holds the
position of Chair for Trauma‐ and Reconstructive Surgery
at the Humboldt & Free University of Berlin as well is the
Director of the Centre for musculoskeletal Surgery at the
Charité Hospital in Berlin.
From 2004 until 2016 Michael Schuetz was the Chair of
Trauma at the Queensland University of Technology (QUT)
as well as Director of Trauma at the Princess Alexandra
Hospital and remains Adjunct Professor at QUT.
Professor Schuetz’s research interests lie in the fields of
orthopaedic trauma surgery, trauma system management,
fracture healing, regenerative medicine and implant
development. He has published more then 200 peer‐
reviewed publications in high impact international journals
including The lancet, Critical Care, Acta biomaterialia,
Biomaterials and Science Translational Medicine. Michael
has attracted over $8.5 million in funding to support his
research from national and international granting
organizations, including four Australian Research Council
(ARC) Linkage Project Grants, one ARC Discovery Grant,
one National Health and Medical Research Council
(NHMRC) Development Grant and one National and
International Research Alliances Program Grant from the
Queensland Government.
He has also established longstanding strategic partnerships
with key players in the orthopaedic device industry, which
have yielded over $1.5 million in funding for his research
program.
Professor Schuetz is a leader in advancing clinical practice
in traumatology. He served as Chairman of the Asia Pacific
Working Group on Implant Design Modifications form
2006‐2011, focusing on the development of world first
orthopaedic implants designed specifically for the
anatomical characteristics of Asia Pacific populations. Prof
Schuetz was a core member of the Queensland Trauma
Plan and inaugural chair of the State‐wide Clinical Network
for Trauma in Queensland from 2007‐2010. He served as
Chair of the AO Research Foundation Institute Advisory
Committee (Davos, Switzerland) from 2011 – 2016, and
![Page 45: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/45.jpg)
was member of the Australian Orthopaedic Association
Strategic Research Board, Board Member of the Australian
Orthopaedic Association Trauma Association and member
of the Australian Trauma Committee of the Royal
Australian College of Surgeons. He has also advised the
Australian Government as member of the Protocol
Advisory Sub‐Committee, and as member of the Specialist
Orthopaedic Clinical Advisory Group, both reporting to the
Department of Health and Ageing.
In 2014 Michael received the Research Award of the
Australian Orthopaedic Association (AOA).
More recently became Chairman of the AO Incubator
Board / Zuerich CH ‐ fostering “Proof of Concept” projects
in the field of orthoapedic trauma with an annual budget
of 5mill CHF.
![Page 46: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/46.jpg)
P: LEVI SHAPIRO
Founder, mHealth, Israel
LEVI SHAPIRO
Levi Shapiro is the Founder of mHealth Israel, a non profit
supporting Israel’s digital health startup community, with
more than 4,000 members. mHealth Israel hosts Israel’s
largest digital health conference, September 14th, with
more than 700 health tech innovators. Levi is also an
Adjunct Professor at IDC Herzliya, in the Adelson School of
Entrepreneurship. He writes about healthcare and
technology in the Jerusalem Post and advises several
prominent global medtech and biotech companies.
During a career spanning more than two decades,
including seven years in Beijing and Tokyo, Mr. Shapiro
launched new business units (IBM), new products and
services (Toyota) and a variety of technology startups (Two
Minute Television, Snack Mobile, etc). He is an investor
and Board Member in several Israeli connected health
startups and formerly a General Partner in the Israel‐based
venture capital firm, Veritas. Mr. Shapiro holds degrees
from Tulane (BA), Cornell (Asian Studies) and MIT (MBA).
![Page 47: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/47.jpg)
P: BENJAMIN SOFFER
Head, T3 ‐ Technion
Technology Transfer, Haifa
BENJAMIN SOFFER
Benjamin Soffer joined the Technion as head of T3 ‐
Technion Technology Transfer office in 2005. As part of his
duties at T3, Mr. Soffer is responsible for the establishment
of startup companies and the commercialization of
technologies arising from the Technion research. His
Experience spans over 25 years in the areas of investment,
industry and government in Israel, Europe, and the United
States. In addition, Mr. Soffer serves as CEO of AMIT, a
Technion Incubator for biomedical innovation; CEO of the
Technion DRIVE Accelerator, and Chairman of the ITTN –
The Israeli Technology Transfer Organization. In addition
Mr. Soffer serves on the boards of directors of numerous
high growth companies. Prior to his position at the
Technion, Mr. Soffer served as managing director of
TopNotch Capital ‐ and was as an investment advisor at
Highbridge Capital. Between 1999 and 2003 he served as
Israel's Economic attaché in Boston. There, Mr. Soffer was
responsible for enhancing economic and business relations
between Israel and the US Northeast region through
private equity investments, joint ventures and trade. Prior
to his tenure in Boston, Mr. Soffer served as special advisor
to Dr. Orna Berry, Israel's chief scientist at the Ministry of
Industry and Trade (currently known as Israel Innovation
Authority) , where played a pivotal role in the initiation and
implementation of innovative R&D programs. A certified
lawyer in Israel and in the state of New York, Mr. Soffer has
interned at Israel's Supreme Court and studied law at Tel
Aviv University and at Ludwig Maximilian University in
Munich. Additionally, he studied economics and business
administration at Bar ‐ Ilan University.
![Page 48: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/48.jpg)
K: JUTTA STEINER
Co‐Founder, Parity
Technologies, London
Jutta Steiner
Before starting Parity, I was responsible for IT security and partner integration within the Ethereum Foundation around the launch of the public blockchain in 2015. I am also a co‐founder of Project Provenance Ltd, a London based start‐up that employs blockchain technology to make supply chains more transparent. I advise various projects that use blockchain technology, such as Energy start‐up Grid Singularity.
Originally trained as a Mathematician and hold a PhD in Applied Mathematics , I started my early professional career as an associate for management consultancy McKinsey.
![Page 49: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/49.jpg)
K: ELLEN 'T HOEN
Director, Medicines Law &
Policy and Global Health
Unit University Medical
Centre Groningen, The
Netherlands
ELLEN 'T HOEN
Ellen ‘t Hoen is a lawyer and public health advocate with
over 30 years of experience working on pharmaceutical
and intellectual property policies. She works as an
independent consultant in medicines law and policy for a
number of international organisations and governments
and is a researcher at the Global Health Unit of the
University Medical Center Groningen, The Netherlands.
From 1999 until 2009 she was the director of policy for
Médecins sans Frontières’ Campaign for Access to Essential
Medicines. In 2009 she joined UNITAID to set up the
Medicines Patent Pool (MPP), an initiative that negotiates
patent licenses to ensure access to affordable generic
medicines. She was the MPP’s first executive director until
2012.
She is a member of the Lancet Commission on Essential
Medicines Policies, the Advisory Board of Universities
Allied for Essential Medicines (UAEM) and the Editorial
Board of the Journal of Public Health Policy.
In 2005, 2006, 2010 and 2011 she was listed as one of the
50 most influential people in intellectual property by the
journal Managing Intellectual Property.
She has published widely and is the author of several
books. In 2017 she received the Prix Prescrire for her latest
book “Private Patents and Public Health: Changing
intellectual property rules for public health.”
www.medicineslawandpolicy.org
![Page 50: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/50.jpg)
K: EVERT JAN VAN LENTE
Director EU‐Affairs, AOK‐
Bundesverband, Berlin
EVERT JAN VAN LENTE
Evert Jan van Lente is Director EU‐Affairs of the AOK‐
Bundesverband, Germany. He is involved in developments
in the health sector on European level, especially in
pharmaceuticals, medical devices, e‐ and mHealth, etc. He
is based in Brussels and Berlin. The AOK‐Group is the
leading statutory health insurance with 25 Million insured
persons in all states of Germany.
Before working on EU level he was Director of the Care
Management / Contracting Department of AOK‐Federal
Association, responsible for care management and
prevention. He was a management consultant in the
Netherlands, served as deputy director of a company
specialized on IT‐Services for health funds in Germany and
headed the AOK contracting department of a regional AOK
organization in Hannover.
He studied economics in Amsterdam (Netherlands) and
Goettingen (Germany).
Mr. van Lente is since 20 years an international consultant
for health financing and organization and is lecturer at the
University Ulm and the Bonn‐ Rhein‐Sieg University of
Applied Science.
![Page 51: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/51.jpg)
P: ANITA KATHARINA WAGNER
Associate Professor, Harvard
Medical School & Harvard
Pilgrim Health Care Institute,
Cambridge MA
ANITA KATHARINA WAGNER
Anita Katharina Wagner is a clinical pharmacist,
pharmacoepidemiologist, and health policy
researcher. She leads research and training programs to
help generate evidence for policy decisions on medicines in
health systems. Her current research focuses on health
system questions around cancer therapies. She serves as
pharmacoepidemiologist in the FDA’s Sentinel Initiative, a
national system that tracks the safety of pharmaceuticals
in the United States; co‐directs the Harvard Medical School
Fellowship in Health Policy and Insurance Research and the
Department of Population Medicine Center for Cancer
Policy and Program Evaluation; and is a Fellow at the
Harvard Medical School Center for Bioethics.
Dr. Wagner received a Master of Public Health degree in
international health and Doctor of Public Health degree in
epidemiology from the Harvard School of Public Health.
She holds a doctorate in clinical pharmacy from the
Massachusetts College of Pharmacy and Allied Health
Sciences and a German master‐equivalent degree in
pharmacy.
For the full bio please
visit: www.populationmedicine.org/awagner.
![Page 52: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/52.jpg)
K: MICHAEL WALLACH
Director, SPARK Australia,
University of Technology
Sydney (UTS), Sydney,
Australia
MICHAEL WALLACH
Professor Michael Wallach has over 30 years of experience
in basic and applied molecular parasitology with a
background in both academic and industrial science. He did
his training at the University of Michigan (B Sc) and the
Hebrew University of Jerusalem (PhD), which he completed
in 1980. From 1980‐1984 he did a post‐doctoral fellowship
at the Rockefeller University, New York, NY under
Professor William Trager in the area of malaria vaccine
development and in 1984 he took up the position as a
lecturer in Parasitology at the Hebrew University,
Jerusalem, Israel.
From 1991‐1993 Professor Wallach spent a sabbatical and
an additional year working at the Institute of Microbiology,
University of Bern, Switzerland where he led a group that
validated a novel vaccine for coccidiosis in chickens (a
devastating intestinal parasitic disease). He then returned
to Israel to commence a period of work in industry at the
Veterinary Division of Teva Pharmaceuticals Ltd. to bring
his vaccine to the market. He completed the development
of the product and the vaccine was launched in several
countries around the world in 2002.
As a result of the successful translation of his research in
parasitology, Professor Wallach was appointed (Sept.
2002) as the Inaugural Director of the Institute for the
Biotechnology of Infectious Diseases (IBID) at the
University of Technology, Sydney, Australia. During the
period of 2002‐2008, the institute grew to over 60
scientists working on a variety of Veterinary and Human
infectious diseases with the aim to come up with real
solutions to some of the world’s most challenging health
problems. Several successful translational projects were
developed as a result of Professor Wallach’s work during
that period, which under his mentorship, has continued
until today.
In 2013, Prof. Wallach was appointed as the inaugural
director of the SPARK Sydney program, which was
established to emulate the SPARK program in translational
medicine developed at the Stanford University School of
Medicine, USA. In 2015, Professor Wallach played a key
role in the establishment of a Global SPARK consortium,
which was formally recognized by representatives of
SPARK programs from around the world in Taipei, Taiwan.
![Page 53: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/53.jpg)
The goal is to greatly increase the translational outcomes
from research by academic staff from all participating
institutions. In 2017, SPARK Global members came
together in Tokyo to discuss the way in which SPARK
programs will work together as a consortium into the
future, and the discussion will continue in Berlin at the
Charité in 2018. Already the consortium has grown to
include 54 prestigious institutions from 15 countries.
Professor Wallach is a core member of the steering
committee for this global initiative.
![Page 54: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/54.jpg)
W: MARCO WINZER
Investment Manager, High‐
Tech Gründerfonds, Bonn
MARCO WINZER
Marco Winzer has been with High‐Tech Gründerfonds
since its foundation and has helped to establish the fund.
The economics graduate has many years of experience in
financing start‐ups in the life sciences industry and has
supported a number of start‐ups all along the value chain
of the ‘Venture Capital Model’ – from seed financing to
successful exit. Before working for HTGF, the Partner
acquired expertise in consulting start‐ups and held various
positions at the Business Innovation Center Kaiserslautern
as well as the Technologie‐Beteiligungsgesellschaft and
development bank KfW.
![Page 55: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/55.jpg)
K: H. E. LYNETTE WOOD
Australian Ambassador to
Germany, Berlin
H. E. LYNETTE WOOD
In Canberra, Ms Wood was First Assistant Secretary,
International Division with the Department of the Prime
Minister and Cabinet (PM&C). She has served as Assistant
Secretary, Middle East Branch and Executive Branch at the
Department of Foreign Affairs and Trade (DFAT). Ms Wood
has also served overseas with postings in Canada and
Germany.
Ms Wood holds a Master of Arts (International Relations)
from the Australian National University, a Graduate
Diploma in Foreign Affairs and Trade from Monash
University and a Bachelor of Arts (Honours) from the
University of Sydney.
![Page 56: JANDEL T. ALLEN DAVIS - Stiftung Charité...Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign. Dr. Allen‐Davis](https://reader034.vdocuments.mx/reader034/viewer/2022050508/5f98e92c86db2a34941f59f8/html5/thumbnails/56.jpg)
K: ROLF ZETTL
CFO & Member of the
Executive Board, Berlin
Institute of Health, Berlin
ROLF ZETTL
Rolf Zettl has over 25 years of management experience in
the life science and research area. He was the founding
managing director of the resource center of the German
genome project and co‐founder and CFO/CEO of biotech
companies. He then moved to the Charité – University
Medicine Berlin where he was head of corporate
development. From 2008 he worked as managing director
of the Helmholtz‐Association of German research centers,
the largest research organization in Germany, before he
moved just recently to the Berlin Institute of Health as its
CFO and member of the executive board. For his whole
professional career, Rolf was involved in tech transfer,
business development, and financing activities. He will
built on this knowledge to establish an ecosystem for
innovation at the Berlin Institute of Health. Rolf is a
biologist by training and did his PhD at the Max Planck
Institute for plant breeding research in Cologne, Germany.